title: [Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis].
abstract: OBJECTIVE
  To study the methods of surgery for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (TTPV).
  
  
  METHODS
  To Analyze and summarize the clinical information from 138 HCC patients with tumor thrombi in portal vein collected during January 1990 and January 2003.
  
  
  RESULTS
  Thirty-seven patients receiving palliative therapy died from 1 to 8 months, and average survival time is 3.9 months. 101 patients had operation treatment, 23 of them underwent hepatoma resection, and average survival time was 10.9 months; 78 patients underwent hepatoma resection and removal of tumor thrombi, and average survival time was 26.8 months. 52 of whom underwent hepatic artery and portal vein chemoembolization, the 1-, 3-, 5-year survival rates was 96.2%, 51.9%, 11.5%, the 1-, 3-, 5-year survival rates of the 26 patients who didn't undergo chemoembolization were 76.9%, 23.1%, 0%.
  
  
  CONCLUSIONS
  Operation treatment can comparatively extend the survival time of hepatocellular carcinoma with tumor thrombi in portal vein patients, and the best choice is hepatoma resection and removal of tumor thrombi, hepatic artery and portal vein chemoembolization after operation can enhance the effect.
authors.affiliation: Department of General Surgery, Guangdong Provincial People Hospital, Guangzhou 510080, China. benson_lau@hotmail.com
authors.forename: Yu-bin
authors.initials: YB
authors.lastname: Liu
authors.forename: Zhi-xiang
authors.initials: ZX
authors.lastname: Jian
authors.forename: Jin-rui
authors.initials: JR
authors.lastname: Ou
authors.forename: Zi-xian
authors.initials: ZX
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein / Q000473:pathology*; D012189:Retrospective Studies; D015996:Survival Rate